Wall Street analysts predict that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will report $6.69 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with estimates ranging from $4.50 million to $8.80 million. Pieris Pharmaceuticals reported sales of $18.15 million during the same quarter last year, which indicates a negative year-over-year growth rate of 63.1%. The company is expected to issue its next earnings report on Friday, March 8th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year sales of $30.66 million for the current year, with estimates ranging from $28.70 million to $33.00 million. For the next financial year, analysts expect that the firm will report sales of $22.74 million, with estimates ranging from $12.00 million to $31.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 18.07%. The business had revenue of $8.35 million during the quarter, compared to analyst estimates of $6.16 million.

PIRS has been the topic of several recent analyst reports. ValuEngine downgraded shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 10th. BidaskClub downgraded shares of Pieris Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, September 15th. HC Wainwright set a $5.00 target price on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. Finally, Cowen reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a report on Sunday, November 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $10.00.

In other news, Director Christopher P. Kiritsy bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The shares were purchased at an average price of $5.11 per share, for a total transaction of $25,550.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $51,100. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 5.07% of the company’s stock.

Large investors have recently bought and sold shares of the company. Acadian Asset Management LLC increased its holdings in shares of Pieris Pharmaceuticals by 2.0% during the 3rd quarter. Acadian Asset Management LLC now owns 2,167,227 shares of the biotechnology company’s stock worth $12,136,000 after purchasing an additional 42,354 shares during the period. Alpine Global Management LLC increased its holdings in shares of Pieris Pharmaceuticals by 125.0% during the 2nd quarter. Alpine Global Management LLC now owns 45,000 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 25,000 shares during the period. GSA Capital Partners LLP increased its holdings in shares of Pieris Pharmaceuticals by 1,516.2% during the 2nd quarter. GSA Capital Partners LLP now owns 269,900 shares of the biotechnology company’s stock worth $1,368,000 after purchasing an additional 253,200 shares during the period. Aquilo Capital Management LLC bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth about $10,013,000. Finally, BlueMountain Capital Management LLC bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth about $500,000. Institutional investors own 65.36% of the company’s stock.

Shares of PIRS stock remained flat at $$3.51 on Wednesday. 428,334 shares of the company traded hands, compared to its average volume of 569,235. Pieris Pharmaceuticals has a 1-year low of $3.04 and a 1-year high of $9.75. The firm has a market cap of $190.07 million, a price-to-earnings ratio of -8.78 and a beta of 1.88.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Further Reading: What are different types of coverage ratios?

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.